Bristol-Myers Squibb Company (NYSE:BMY) went down by -1.86% from its latest closing price compared to the recent 1-year high of $80.59. The company’s stock price has collected -3.00% of loss in the last five trading sessions. Barron’s reported on 09/12/22 that Bristol Myers, Carvana, MicroStrategy, Adobe, and More Stock Market Movers
Is It Worth Investing in Bristol-Myers Squibb Company (NYSE :BMY) Right Now?
Bristol-Myers Squibb Company (NYSE:BMY) scored a price-to-earnings ratio above its average ratio, recording 23.33 x from its present earnings ratio. Plus, the 36-month beta value for BMY is at 0.41. Opinions of the stock are interesting as 10 analysts out of 21 who provided ratings for Bristol-Myers Squibb Company declared the stock was a “buy,” while 1 rated the stock as “overweight,” 8 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $81.18, which is $11.25 above the current price. BMY currently public float of 2.13B and currently shorts hold a 1.06% ratio of that float. Today, the average trading volume of BMY was 10.26M shares.
BMY’s Market Performance
BMY stocks went down by -3.00% for the week, with a monthly drop of -5.34% and a quarterly performance of -4.85%, while its annual performance rate touched 14.48%. The volatility ratio for the week stands at 2.13% while the volatility levels for the past 30 days are set at 2.28% for Bristol-Myers Squibb Company. The simple moving average for the period of the last 20 days is -0.51% for BMY stocks with a simple moving average of -0.69% for the last 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Berenberg repeating the rating for BMY by listing it as a “Hold.” The predicted price for BMY in the upcoming period, according to Berenberg is $76 based on the research report published on September 14th of the current year 2022.
Morgan Stanley gave a rating of “Underweight” to BMY, setting the target price at $64 in the report published on April 06th of the current year.
BMY Trading at -3.36% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.90% of loss for the given period.
Volatility was left at 2.28%, however, over the last 30 days, the volatility rate increased by 2.13%, as shares sank -6.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.89% lower at present.
During the last 5 trading sessions, BMY fell by -3.00%, which changed the moving average for the period of 200-days by +27.73% in comparison to the 20-day moving average, which settled at $70.29. In addition, Bristol-Myers Squibb Company saw 12.57% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BMY starting from Caforio Giovanni, who sale 50,000 shares at the price of $71.84 back on Sep 15. After this action, Caforio Giovanni now owns 501,104 shares of Bristol-Myers Squibb Company, valued at $3,592,000 using the latest closing price.
Powell Ann, the EVP, Chief Human Resources of Bristol-Myers Squibb Company, sale 25,000 shares at $70.75 during a trade that took place back on Sep 14, which means that Powell Ann is holding 50,476 shares at $1,768,750 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- +20.57 for the present operating margin
- +57.69 for the gross margin
The net margin for Bristol-Myers Squibb Company stands at +15.08. Equity return is now at value 19.30, with 6.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.